MaxCyte stock rallies on initial Q3 revenue, higher FY26 outlook
Related news
- INEO Tech reports FY results
- Sizzle Acquisition reports 1H results
- ImmunityBio's Anktiva gains expanded bladder cancer approval
-
Apple asks judge to overturn $5.7B patent verdict in Taction case
- U.S. to halt Obamacare benefits for 189,000 duplicate and deceased enrollees
- Scienture Holdings reports preliminary Q3 results
- SEC to hold committee meeting to discuss IPO modernization, crowdfunding
-
Earnings call transcript: Ichigo posts mixed H1 2027 results as buybacks continue